Alectinib: A Review in Advanced, ALK-Positive NSCLC
- PMID: 30030733
- DOI: 10.1007/s40265-018-0952-0
Alectinib: A Review in Advanced, ALK-Positive NSCLC
Abstract
Alectinib (Alecensa®) is a potent and highly selective anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor. Oral alectinib monotherapy is approved in the EU as first-line treatment for adults with advanced ALK-positive non-small cell lung cancer (NSCLC) and for the treatment of adults with advanced ALK-positive NSCLC previously treated with crizotinib. In the USA, alectinib is indicated for the treatment of adults with ALK-positive metastatic NSCLC. The recommended dosage for alectinib in the EU and USA is 600 mg twice daily. Well-designed phase III studies in patients with ALK-positive NSCLC showed that during up to ≈ 19 months' follow-up, progression-free survival (PFS) was significantly improved with alectinib relative to crizotinib as first-line therapy (ALEX study), and relative to chemotherapy in patients previously treated with crizotinib and platinum-doublet chemotherapy (ALUR study). Central nervous system (CNS)-related outcomes were significantly improved with alectinib in both these settings. Two phase II registrational studies (NP28673 and NP28761) in patients previously treated with crizotinib also demonstrated the efficacy of alectinib, as assessed by objective response rates (ORRs), during up to 21 months' follow-up. Overall, alectinib had a manageable tolerability profile in these settings, with most adverse events (AEs) of mild or moderate severity. Current evidence indicates that alectinib is an important treatment option for patients with advanced ALK-positive NSCLC who are previously untreated or those previously treated with crizotinib. Given its efficacy and tolerability, current guidelines include alectinib as a treatment option in these settings, with the NCCN guidelines recommending it as a preferred option for first-line therapy.
Similar articles
-
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.N Engl J Med. 2017 Aug 31;377(9):829-838. doi: 10.1056/NEJMoa1704795. Epub 2017 Jun 6. N Engl J Med. 2017. PMID: 28586279 Clinical Trial.
-
The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.Future Oncol. 2018 Aug;14(18):1875-1882. doi: 10.2217/fon-2018-0027. Epub 2018 Mar 14. Future Oncol. 2018. PMID: 29536761 Review.
-
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.Lancet. 2017 Jul 1;390(10089):29-39. doi: 10.1016/S0140-6736(17)30565-2. Epub 2017 May 10. Lancet. 2017. PMID: 28501140 Clinical Trial.
-
Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.Drugs. 2015 Jan;75(1):75-82. doi: 10.1007/s40265-014-0329-y. Drugs. 2015. PMID: 25428710 Review.
-
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.J Clin Oncol. 2016 Mar 1;34(7):661-8. doi: 10.1200/jco.2015.63.9443. Epub 2015 Nov 23. J Clin Oncol. 2016. PMID: 26598747 Clinical Trial.
Cited by
-
Non-small cell lung cancer with bone metastasis and pneumocystis pneumonia in a pregnant woman: a case report and literature review.BMC Infect Dis. 2023 Nov 14;23(1):792. doi: 10.1186/s12879-023-08790-z. BMC Infect Dis. 2023. PMID: 37964211 Free PMC article. Review.
-
Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer.Pharmaceutics. 2023 Apr 16;15(4):1252. doi: 10.3390/pharmaceutics15041252. Pharmaceutics. 2023. PMID: 37111737 Free PMC article. Review.
-
Successful Treatment with Brigatinib after Alectinib-Induced Hemolytic Anemia in Patients with Metastatic Lung Adenocarcinoma-A Case Series.Curr Oncol. 2022 Dec 30;30(1):518-528. doi: 10.3390/curroncol30010041. Curr Oncol. 2022. PMID: 36661690 Free PMC article.
-
A pregnant patient with ALK-positive non-small cell lung cancer treated with alectinib: A case report and review of the literature.Oncol Lett. 2022 Dec 20;25(2):54. doi: 10.3892/ol.2022.13640. eCollection 2023 Feb. Oncol Lett. 2022. PMID: 36644155 Free PMC article.
-
High incidence and reversible bradycardia events following alectinib initiation.Thorac Cancer. 2023 Feb;14(5):479-488. doi: 10.1111/1759-7714.14769. Epub 2022 Dec 19. Thorac Cancer. 2023. PMID: 36535917 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical